Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia

A novel agent reduced the need for blood transfusions in two separate patient populations: myelodysplastic syndromes (MDS) and beta-thalassemia.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM).
Source: Einstein News - Category: Universities & Medical Training Source Type: news
Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported in the Jan. 9 New England Journal of Medicine.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
AbstractIron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI ...
Source: Clinical and Experimental Medicine - Category: Research Source Type: research
In this study, the abnormal PNH clones were detected using a single tube FLAER based testing and two tubes non-FLAER based testing in all cases of PNH (n = 12), healthy subjects (n = 18) and AA/MDS with PNH clone (n = 9) and compared with clinical and laboratory features at di agnosis. The receiver operator curve (ROC) analysis defined the optimal cut-offs for FLAER in granulocytes (>  0.7%) and monocytes (>  0.9%). There was significant positive correlation between FLAER and non-FLAER based testing in these cells (r >  0.3 andp 
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
AbstractSubclinical PNH can be present in patients with bone marrow failure like aplastic anemia and myelodysplastic syndrome (MDS). Such clone may have prognostic and therapeutic implications. In literature around 1 –10% MDS cases have shown a PNH clone, however, data from India is relatively scarce. A high sensitivity PNH assay was employed using a single tube combination of FLAER, CD157, CD64, CD15 and CD45 antibodies in adult patients of MDS at presentation. A clone size of  >  0.01% was taken as significant. A total of 30 patients were included. PNH clone was present in 30% cases. Correlati...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Abstract Refractory anaemia (RA) among myelodysplastic syndrome (MDS) is associated with a partial functional iron deficit and may require transfusions. In low-risk lymphoma and solid tumour patients, iron support improves erythropoietin (EPO) cost-effectiveness in treating anaemia. The aim of this study is to see if oral sucrosomial iron support improves the cost-effectiveness of EPO treatment in MDS patients affected by low-risk RA. We treated patients with EPO only or with EPO plus oral sucrosomial iron or intravenous (i.v.) iron. The need for transfusions was lowest in the group taking oral iron (p = 0.016) or...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
This study involves a 49-year-old male, who for three years suffered with a myelodysplastic syndrome and who needed frequent blood transfusions. One day following a transfusion, he presented fever and abdominal pain. The fever became persistent and only improved temporarily with two cycles of intravenous ciprofloxacin. Nearly 120 days after beginning the second cycle of treatment, he had experienced a weight loss of 16 kg and recurring fever. Screening for fever of unknown origin was conducted, including Bartonella infection. No etiology could be found. The patient improved with an antimicrobial regimen composed of oral do...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - Category: Tropical Medicine Authors: Tags: Rev Inst Med Trop Sao Paulo Source Type: research
Abstract Patients with myelodysplastic syndrome (MDS) often require blood transfusion and anticancer therapy; however, elderly patients are intolerant to the associated side effects of anticancer therapy. Because L-leucine can be used to treat Diamond-Blackfan anemia, which is caused by defects in ribosomal protein (RP) genes, resulting in increased in vivo hemoglobin synthesis, it is possible that some MDS patients who have aberrations in their RP genes could also be effectively treated with L-leucine. In the present study, we investigated the effects of L-leucine on hematopoietic function (reticulocyte count), r...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
AbstractObjectiveTo investigate the relation of blood arsenic concentration (BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder ( 青黄散, QHP) in patients with myelodysplastic syndrome (MDS).MethodsTotally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed.ResultsAfter 2 courses of treatment, the total effective rate w...
Source: Chinese Journal of Integrative Medicine - Category: Internal Medicine Source Type: research
AbstractLeukemia is one of the most aggressive hematological malignancies. Leukemia stem cells account for the poor prognosis and relapse of the disease. Decades of investigations have been performed to figure out how to eradicate the leukemia stem cells. It has also been known that cancer cells especially solid cancer cells use energy differently than most of the cell types. The same thing happens to leukemia. Since there are metabolic differences between the hematopoietic stem cells and their immediate descendants, we aim at manipulating the energy sources with which that could have an effect on leukemia stem cells while...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
More News: Blood Transusion | Cancer & Oncology | Health | Hematology | Myelodysplastic Syndrome